Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Breast Cancer Female Clinical Trial

— SOLTI NEOPARP  

Official title:

Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01204125
• Other study ID #: TCD11419
• Secondary ID: 2010-018960-17
• Status: Completed
• Phase: Phase 2
• First received: September 13, 2010
• Last updated: March 21, 2017
• Start date: September 2010
• Est. completion date: February 2017

Study information

• Verified date: March 2017
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

• to assess the pathological Complete Response (pCR) rate in the breast of patients treated in following combinations: SAR240550 twice-weekly + weekly paclitaxel, SAR240550 weekly+ weekly paclitaxel, and weekly paclitaxel single agent as calibrator.

Secondary objectives are:

• pCR rate in the breast and axilla,

• Radiological/clinical objective response rate (ORR), breast conservation rate, disease free survival (DFS), and overall survival (OS), in each treatment arm,

• Safety profiles of study combinations and of the single agent reference treatment,

• Molecular characteristics of the tumor tissue and peripheral blood mononuclear cells (PBMC) and any correlation between the biological activity of the study treatment and the disease outcome.

Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.

Description:

Active study treatment will be given either as twice weekly administration (Day 1 and Day 4) or as weekly administration (Day 1) for a maximum of 24 infusions for Arm A and for a maximum of 12 infusions for Arm B. In all study arms, treatment will be given until definitive surgery, the first sign of disease progression, unacceptable toxicity or withdrawal of patient consent.

Definitive surgery will be performed within 2 to 4 weeks after the last dose of study treatment.

Patients who complete all the study treatment or who withdraw consent or experience intolerable toxicity will undergo surgery according to local practices.

The cut-off date for the primary analyses will be 30 days after the last study treatment administration or the date of the definitive surgery, whichever comes last.

The maximum follow up for each individual patient will be until death or 5 years after the definitive surgery date whatever happens first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: February 2017
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Histologically confirmed Stage II-IIIA invasive breast cancer eligible for definitive surgery and Estrogen Receptor (ER)-negative, Progesterone receptor (PgR)-negative and Human epidermal growth factor receptor 2 (HER2) non-overexpressing by Immunohistochemistry (IHC) (0+, 1+) or fluorescence in situ hybridization (FISH negative, ratio <1.8) or IHC (2+, 3+) /FISH-negative.

• The primary tumor must be > 2cm in diameter measured by physical examination and mammography (mandatory) plus either echography or Magnetic Resonance Imaging (MRI)

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Adequate bone marrow reserve

• Adequate liver and renal function.

• Age > or = 18 years

Exclusion criteria:

• Any prior treatment for primary breast cancer.

• Bilateral or multicentric breast cancer.

• Other primary tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix.

• Pre-existing peripheral neuropathy grade > or = 2 as per National Cancer Institute Common Toxicity Criteria for Adverse Event (NCI CTCAE) at randomization.

• Any history of medical (e.g., cardiovascular, uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection) or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results

• Pregnancy or breastfeeding women.

• Women of childbearing potential (<2 years after the last menstruation) not using effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug.

• Requirement for radiation therapy concurrent with study anticancer treatment. Patients who require breast or chest wall radiation therapy after surgery are eligible.

• Known hypersensitivity to any of the study drugs or excipients

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms
• Triple Negative Breast Neoplasms

Intervention

Drug:
• paclitaxel
Pharmaceutical form:solution for infusion Route of administration: intravenous
• Iniparib (SAR2405550 -BSI-201)
Pharmaceutical form : solution for infusion Route of administration :Intravenous

Locations

Country	Name	City	State
France	Investigational Site Number 250001	Besancon Cedex
France	Investigational Site Number 250004	Bordeaux
France	Investigational Site Number 250006	Bron Cedex
France	Investigational Site Number 250003	Paris Cedex 10
France	Investigational Site Number 250002	Toulouse
France	Investigational Site Number 250005	Villejuif
Germany	Investigational Site Number 276003	Erlangen
Germany	Investigational Site Number 276004	Hamburg
Germany	Investigational Site Number 276002	Köln
Germany	Investigational Site Number 276001	Mönchengladbach
Spain	Investigational Site Number 724001	Barcelona
Spain	Investigational Site Number 724009	Cáceres
Spain	Investigational Site Number 724013	Córdoba
Spain	Investigational Site Number 724006	Islas Baleares
Spain	Investigational Site Number 724012	Jaén
Spain	Investigational Site Number 724002	Lérida
Spain	Investigational Site Number 724005	Madrid
Spain	Investigational Site Number 724016	Madrid
Spain	Investigational Site Number 724007	Reus
Spain	Investigational Site Number 724018	Santiago De Compostela
Spain	Investigational Site Number 724010	Sevilla
Spain	Investigational Site Number 724017	Sevilla
Spain	Investigational Site Number 724003	Torrevieja
Spain	Investigational Site Number 724011	Valencia
Spain	Investigational Site Number 724015	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
Sanofi	SOLTI Breast Cancer Research Group

Countries where clinical trial is conducted

France,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review		at the time of definitive surgery
Secondary	Pathological Complete Response (pCR) rate in the breast and axilla		at the time of definitive surgery
Secondary	Objective Response Rate(ORR) defined in the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as complete response rate + partial response rate		at the time of definitive surgery
Secondary	Breast conservation rate		at the time of definitive surgery
Secondary	Disease Free Survival rate (DFS)		up to a maximum of 5 years after definitive surgery
Secondary	Overall Survival (OS)		up to a maximum of 5 years after definitive surgery
Secondary	Safety parameters (number of patients AE, SAE or AEPM)		up to a maximum of 5 years after definitive surgery
Secondary	Molecular-biological testing		2 or 3 timepoints during treatment period